![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 19, 2010 11:54:14 AM
BEVERLY, MA--(Marketwire - 01/19/10) - INVO Bioscience, Inc. (OTC.BB:IVOB - News), a medical device company focused on treatment options for patients diagnosed with infertility, announced the signing of Bulgarian distribution company BioGenini Medical EOOD. BioGenini Medical is a medical device distribution and research company that is now looking into new concepts that will allow for affordable infertility treatment. INVO Bioscience CEO Katie Karloff stated, "The shortage of a cost effective treatment has left a lot of couples simply out of reach. I believe that INVO Bioscience partnered with BioGenini can bring an affordable infertility treatment to couples in Bulgaria."
INVOcell product registration was started by BioGenini during the middle of December 2009 and should be completed within the coming months. Bulgaria currently has a dangerously low replacement rate of 1.2 children per couple. A single IVF cycle in Bulgaria is around $3,800 while an average yearly salary in Bulgaria is estimated at $4,602. The government and insurance companies offer no support for IVF. BioGenini will look to expand the INVO procedure first into Bulgaria and if successful may expand INVO into other parts of Eastern Europe.
About the INVO Procedure
The INVOcell and INVO Procedure combine a natural or mild (mild medication) stimulation infertility treatment cycle, using lower amounts of fertility hormones than used in traditional IVF (in vitro fertilization), with intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg retrieval, the woman's eggs (oocytes) are combined with sperm in the INVOcell, a small device, which is then sealed and placed in the woman's vaginal cavity to incubate for three days. When the INVOcell is removed, the anticipated one to two developing embryos are transferred directly into the woman's uterine cavity, where implantation and continued pregnancy can take place.
The company has received European CE Mark approval for the INVOcell in 2008 and launched the product in select countries outside the U.S. The company is also pursuing U.S. Food and Drug Administration 510(k) clearance for the INVOcell.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Recent INVO News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/21/2024 08:39:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:51:16 PM
- INVO Reports Record First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/15/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:30:18 PM
- Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
- INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
- NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
- NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
- INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/24/2023 06:08:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:59:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:04 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM